聚焦季度融资统计2025Q4。Biopharma Financing Biopharma financing during the fourth quarter of 2025 totaled $30bn from 291 deals. Of those, 99 reached $100m or more. The follow-on public offering (FOPO) category made up the highest proportion of deal value, accounting for 37% of the aggregate Q4 financing dollars (see Exhibit 1).
聚焦季度融资统计2025Q4。Biopharma Financing Biopharma financing during the fourth quarter of 2025 totaled $30bn from 291 deals. Of those, 99 reached $100m or more. The follow-on public offering (FOPO) category made up the highest proportion of deal value, accounting for 37% of the aggregate Q4 financing dollars (see Exhibit 1).
聚焦季度融资统计2025Q4。Biopharma Financing Biopharma financing during the fourth quarter of 2025 totaled $30bn from 291 deals. Of those, 99 reached $100m or more. The follow-on public offering (FOPO) category made up the highest proportion of deal value, accounting for 37% of the aggregate Q4 financing dollars (see Exhibit 1).
覆盖 2026 年,全文共 13 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
适合战略规划、产品经理等读者参考。
重点分析了季度融资统计2025Q4等议题。